Novo Nordisk shares fall 20% after company names new CEO and lowers its financial outlook

Novo Nordisk, a Danish pharmaceutical company, faced a significant setback on Tuesday as its shares plummeted by over 20%. The company attributed this decline to the appointment of a new CEO and a downward revision of its profit expectations. The primary reason cited for the lowered projections was the weaker-than-expected sales of Wegovy, a popular weight-loss drug, due to increased competition from generic versions in the market.

In a press release, Novo Nordisk announced that its sales growth for 2025 is now expected to be in the range of 8%-14%, a decrease from the earlier forecast of 13%-21% in May. Similarly, the operating profit growth outlook was revised to 10%-16%, down from the initial projection of 16%-24%. The company attributed these adjustments to the continued use of compounded GLP-1s, slower market expansion, and intensified competition in the industry.

Maziar Mike Doustdar, a seasoned executive with over 30 years of experience at Novo Nordisk, was appointed as the new President and CEO, succeeding Lars Fruergaard Jorgensen. Jorgensen’s departure in May had followed a sharp decline in the company’s stock price, which had fallen by nearly 37% since the beginning of the year.

The market for weight-loss drugs has been impacted by the proliferation of compounded versions of popular medications like Wegovy. Although global sales of Wegovy have been on the rise, competition from these generic alternatives has put pressure on the brand. The FDA’s crackdown on compounding pharmacies selling copycat drugs has not entirely curbed their presence in the market, offering consumers a more affordable option compared to the original branded medications.

Novo Nordisk has taken legal action against entities selling counterfeit semaglutide drugs, the active ingredient in Wegovy and Ozempic. The company expressed concerns about patient safety and emphasized the risks associated with knockoff drugs made with unauthorized ingredients. Novo Nordisk is actively pursuing various avenues, including litigation, to safeguard patients from these illicit products.

As the company navigates these challenges, it remains committed to protecting the integrity of its products and ensuring the safety of consumers. With the appointment of a new CEO and a strategic focus on combating counterfeit drugs, Novo Nordisk aims to regain market confidence and drive sustainable growth in the future.